Kiniksa Pharmaceuticals, Ltd.
KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatoā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$41.59
Price+2.58%
$1.04
1Y
Price
Market Cap
$3.048b
Mid
Price/Earnings 3y Avg5y Avg
92.4x
Premium
Premium
Financials Overview
Key metrics over the past few years+15.2%
EBITDA Margin+10.2%
Net Profit Margin+18.3%
Free Cash Flow MarginRevenue
$597.973m
+41.3%
1y CAGR+40.2%
3y CAGR+148.0%
5y CAGREarnings
$35.918m
+183.2%
1y CAGR-105.3%
3y CAGR-24.9%
5y CAGREPS
$0.45
+175.0%
1y CAGR-105.8%
3y CAGR-26.1%
5y CAGRBook Value
$535.383m
$712.333m
Assets$176.950m
Liabilities$9.718m
DebtDebt to Assets
1.4%
0.2x
Debt to EBITDAFree Cash Flow
$101.733m
+300.3%
1y CAGR+174.8%
3y CAGR+157.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company